Takeda Pharmaceutical Company Limited (TAK): Price and Financial Metrics
GET POWR RATINGS... FREE!
TAK POWR Grades
- Value is the dimension where TAK ranks best; there it ranks ahead of 98.51% of US stocks.
- TAK's strongest trending metric is Growth; it's been moving down over the last 179 days.
- TAK ranks lowest in Momentum; there it ranks in the 8th percentile.
TAK Stock Summary
- Takeda Pharmaceutical Co Ltd's market capitalization of $46,992,899,992 is ahead of 94.24% of US-listed equities.
- The price/operating cash flow metric for Takeda Pharmaceutical Co Ltd is higher than only 0.89% of stocks in our set with a positive cash flow.
- Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for TAK comes in at 2,315.4% -- higher than that of 99.62% of stocks in our set.
- Stocks that are quantitatively similar to TAK, based on their financial statements, market capitalization, and price volatility, are CAJ, CMCM, DOW, PHG, and TEL.
- TAK's SEC filings can be seen here. And to visit Takeda Pharmaceutical Co Ltd's official web site, go to www.takeda.com.
TAK Stock Price Chart Interactive Chart >
TAK Price/Volume Stats
| Current price | $14.25 | 52-week high | $17.31 |
| Prev. close | $14.12 | 52-week low | $13.05 |
| Day low | $14.14 | Volume | 1,384,800 |
| Day high | $14.27 | Avg. volume | 2,722,084 |
| 50-day MA | $14.04 | Dividend yield | 3.86% |
| 200-day MA | $14.31 | Market Cap | 44.19B |
Takeda Pharmaceutical Company Limited (TAK) Company Bio
Takeda Pharmaceutical Company Limited is engaged in research and development, manufacturing, sales and marketing, and import and export of pharmaceutical drugs. The Company focuses on the core therapeutic areas of oncology, gastrointestinal, and central nervous system disease.
Latest TAK News From Around the Web
Below are the latest news stories about Takeda Pharmaceutical Co Ltd that investors may wish to consider to help them evaluate TAK as an investment opportunity.
Takeda Inks $2B Gene Therapy Pact With Code BiotherapeuticsTakeda Pharmaceutical Co Ltd (NYSE: TAK ) has signed up for a gene therapy pact, encoding a $2 billion biobucks deal with Code Biotherapeutics across four programs. The collaboration entails deploying Code''s non-viral gene therapies against liver-directed rare disease and central nervous system conditions. Through the agreement, Takeda and Code Bio will design and Full story available on Benzinga.com |
Real-World Analysis Show Takeda''s Alofisel Clinical Remission Rate At Six-MonthsTakeda Pharmaceutical Co Ltd (NYSE: TAK ) announced the first six-month interim analysis results from INSPIRE study evaluating the Real-World Effectiveness and Safety of Alofisel (darvadstrocel). The study demonstrated clinical remission in 65% of patients in both cohorts evaluated at six months, with Crohn''s disease … Full story available on Benzinga.com |
Takeda''s Alofisel shows remission in patients with Crohn’s diseaseTakeda Pharmaceutical (TAK) said an interim analysis in a post-approval study of Alofisel showed clinical remission at six months in 65% of patients with Crohn’s disease ((CD)) and… |
Real-World Analysis Show Takeda's Alofisel Clinical Remission Rate At Six-MonthsTakeda Pharmaceutical Co Ltd (NYSE: TAK) announced the first six-month interim analysis results from INSPIRE study evaluating the Real-World Effectiveness and Safety of Alofisel (darvadstrocel). The study demonstrated clinical remission in 65% of patients in both cohorts evaluated at six months, with Crohn's disease (CD) and complex perianal fistulas. Data were presented at the European Crohn's and Colitis Organisation (ECCO) 2022 Congress. Clinical response was observed in 73% (57/78) and 74% ( |
Alofisel®▼ (darvadstrocel) Shows Clinical Remission Rate at Six-Months in the Real-World INSPIRE Study Interim Analysis Consistent with the Pivotal Clinical ADMIRE-CD Study1,2OSAKA, Japan & CAMBRIDGE, Massachusetts, February 18, 2022--Takeda (TSE:4502/NYSE:TAK) today announced the first six-month interim analysis results from INSPIRE, in which clinical remission* was observed in 65% of patients in both cohorts who were evaluated at 6 months.1 INSPIRE is a European, observational, multicenter, post-approval, open-enrollment study (EUPAS24267) evaluating the real-world effectiveness and safety of Alofisel (darvadstrocel) in patients with Crohn’s disease (CD) and comple |
TAK Price Returns
| 1-mo | -1.59% |
| 3-mo | -0.21% |
| 6-mo | -6.19% |
| 1-year | -13.19% |
| 3-year | -10.58% |
| 5-year | -43.26% |
| YTD | 4.55% |
| 2021 | -23.58% |
| 2020 | -5.97% |
| 2019 | 19.31% |
| 2018 | -40.08% |
| 2017 | 36.91% |
TAK Dividends
| Ex-Dividend Date | Type | Payout Amount | Change | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Loading social stream, please wait...